APA (7th ed.) Citation

HD, K., J, S., J, H., H, L., M, M., J, M., . . . MH, R. (2025). Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 28(1), 74. https://doi.org/10.1007/s10120-024-01566-7

Chicago Style (17th ed.) Citation

HD, Kim, Shin J, Hyung J, Lee H, Moon M, Ma J, Park YS, and Ryu MH. "Survival Outcomes of Patients with Gastric Cancer Treated with First-line Nivolumab Plus Chemotherapy Based on Claudin 18.2 Expression." Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 28, no. 1 (2025): 74. https://doi.org/10.1007/s10120-024-01566-7.

MLA (9th ed.) Citation

HD, Kim, et al. "Survival Outcomes of Patients with Gastric Cancer Treated with First-line Nivolumab Plus Chemotherapy Based on Claudin 18.2 Expression." Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, vol. 28, no. 1, 2025, p. 74, https://doi.org/10.1007/s10120-024-01566-7.